Europe and the United States account for more than 80% of global sales of new medicines, 75% of global R&D in life sciences, and create and sustain over 1.5 million direct jobs. The Transatlantic Trade and Investment Partnership (TTIP) would boost the world’s largest trading relationship, spur transatlantic investment in life sciences, and foster research cooperation, resulting in improved healthcare and facilitated patient access to innovative medicines on both sides of the Atlantic. This paper aims to highlight the key priorities of the pharmaceutical industry in TTIP. EFPIA supports an ambitious and comprehensive agreement, which addresses regulatory convergence, intellectual property protection and provides for greater market access.